Temodar

(temozolomide)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Temozolomide is used to treat certain types of brain cancer, including glioblastoma and anaplastic astrocytoma. It works by damaging cancer cell DNA to stop them from growing and dividing.[2] Temodar is currently approved and in use across 90 indications[4].[1]

Temodar is one of 1216 small molecule programs targeting Glioma. It is currently in Approved.

Indications

748

Total Trials

Active Trials

1,215

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Optic Nerve GlioblastomaApproved

EpendymomaActive, not recruiting

AstrocytomaActive, not recruiting

Uterine LeiomyosarcomaActive, not recruiting

MetastasisActive, not recruiting

Primitive Neuroectodermal TumorActive, not recruiting

Adult Brainstem GliomaActive, not recruiting

ParagangliomaApproved

Pancreatic Endocrine CarcinomaApproved

GliomaApproved

Active, not recruiting

Optic Nerve GlioblastomaApproved

Approved

EpendymomaPhase 2

Active, not recruiting

AstrocytomaPhase 3

Active, not recruiting

Uterine LeiomyosarcomaPhase 2/Phase 3

Active, not recruiting

MetastasisPhase 2

Active, not recruiting

Primitive Neuroectodermal TumorPhase 2

Active, not recruiting

Adult Brainstem GliomaPhase 2

Active, not recruiting

ParagangliomaApproved

Approved

Pancreatic Endocrine CarcinomaApproved

Approved

Showing 10 of 90 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

8 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Soft Tissue Sarcoma

NCT04200443

Q4 2026

Phase 2Active, not recruiting

Lung Cancer

NCT03728361

Phase 2Recruiting

Locally-Advanced Rectal Cancer

NCT05136326

Phase 3Active, not recruiting

Glioma

NCT00978458

Phase 1/2Active, not recruiting

Glioblastoma

NCT03491683

Phase 1/2Recruiting

Ewing Sarcoma

NCT04901702

Clinical

Trials by Indication[1]

Glioblastoma38 trials

Preoperative Chemoradiation for Glioblastoma

Completed·TTampa General Hospital·Phase 1·NCT02092038·1 enrolled

Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients

Completed·CCenter Eugene Marquis··NCT01345370·300 enrolled

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

Withdrawn·NNRG Oncology·Phase 2/3·NCT04105374

Show 35 more trials

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Active, not recruiting·NNorthwestern University·Phase 1·NCT06410248·30 enrolled

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Recruiting·NNovoCure GmbH·Phase 3·NCT06556563·741 enrolled

NG101m Adjuvant Therapy in Glioblastoma Patients

Not yet recruiting·NNeuGATE Theranostics·Phase 1/2·NCT04373785·52 enrolled

A Phase III Study of Re-Irradiation in Recurrent Glioblastoma

Withdrawn·AAHS Cancer Control Alberta·Phase 3·NCT01830101

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Unknown status·BBassam Abdulkarim·Phase 2·NCT02928575·45 enrolled

A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Unknown status·CCure&Sure Biotech Co., LTD·Phase 2·NCT03650257·150 enrolled

A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma

Completed·UUniversity of Colorado, Denver·Phase 1·NCT00792012·37 enrolled

Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma

Completed·KKing Fahad Medical City·Phase 2·NCT02029573·36 enrolled

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

Active, not recruiting·NNorthwestern University·Phase 1·NCT05236036·60 enrolled

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Recruiting·OOrbus Therapeutics, Inc.·Phase 1·NCT05879367·66 enrolled

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Active, not recruiting· Inovio Pharmaceuticals logo

Inovio Pharmaceuticals·Phase 1/2·NCT03491683·52 enrolled

The Addition of Chloroquine to Chemoradiation for Glioblastoma

Completed·MMaastricht Radiation Oncology·Phase 1·NCT02378532·13 enrolled

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT04477200·68 enrolled

LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas

Unknown status·—·Phase 1/2·NCT05663125·10 enrolled

A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02805179·26 enrolled

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00734526·18 enrolled

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00200161·127 enrolled

Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma

Terminated·IInstitut Cancerologie de l'Ouest·Phase 1·NCT01700569·24 enrolled

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01062425·261 enrolled

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00553150·122 enrolled

Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma

Completed·CCytoVac A/S·Phase 2·NCT02799238·62 enrolled

A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70

Active, not recruiting·UUniversity of Louisville·Phase 1/2·NCT01985087·18 enrolled

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00662506·46 enrolled

A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

Completed· Roche logo

Roche·Phase 2·NCT01860638·296 enrolled

Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients

Unknown status·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT00643825·64 enrolled

Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)

Unknown status·MM.E. van Linde·Phase 1·NCT03463733·54 enrolled

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Not yet recruiting·VVastra Gotaland Region·Phase 3·NCT06419946·200 enrolled

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Completed·DDenovo Biopharma LLC·Phase 3·NCT03776071·260 enrolled

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

Completed·EExelixis·Phase 1·NCT00960492·26 enrolled

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Completed·WWashington University School of Medicine·Phase 1/2·NCT02715609·35 enrolled

A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma

Completed· Roche logo

Roche·Phase 2·NCT00967330·182 enrolled

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Active, not recruiting·MMayo Clinic·Phase 2·NCT03197506·52 enrolled

Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Completed·MMassachusetts General Hospital·Phase 2·NCT03139916·36 enrolled

Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00365222·1 enrolled

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

Terminated·SSynerGene Therapeutics, Inc.·Phase 2·NCT02340156·1 enrolled

Glioblastoma Multiforme28 trials

5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03291990·3 enrolled

Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·CCanadian Cancer Trials Group·Phase 3·NCT00482677·562 enrolled

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00555399·55 enrolled

Show 25 more trials

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00316849·56 enrolled

Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00686725·99 enrolled

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00869401·217 enrolled

A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse

Completed·—·Phase 2·NCT02330991·204 enrolled

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

Completed·—·Phase 2·NCT00323115·11 enrolled

Radiation Boost for Newly Diagnosed Glioblastoma Multiforme

Terminated·MMethodist Healthcare·Phase 1/2·NCT00376103·3 enrolled

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Unknown status·LLeaf Vertical Inc.·Phase 1/2·NCT03607643·160 enrolled

MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma

Terminated·MMassachusetts General Hospital·N/A·NCT00756106·15 enrolled

BG & TMZ Therapy of Glioblastoma Multiforme

Completed·SStanton Gerson MD·Phase 1·NCT01269424·10 enrolled

Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme

Completed·UUniversity of Colorado, Denver·Phase 2·NCT01209442·30 enrolled

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00498927·47 enrolled

Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

Completed·KKaty Peters·Phase 2·NCT00979017·41 enrolled

Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00841555·9 enrolled

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Completed·NNovoCure GmbH·Phase 3·NCT00916409·700 enrolled

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00544817·47 enrolled

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT01149850·50 enrolled

A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme

Completed· Roche logo

Roche·Phase 2·NCT01115491·32 enrolled

Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme

Completed·CCentre Leon Berard·Phase 3·NCT00820963·70 enrolled

Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·CCancer Research UK·Phase 1·NCT01222221·45 enrolled

Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00099125·170 enrolled

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00050986·55 enrolled

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

Completed·CCelldex Therapeutics·Phase 2·NCT00458601·82 enrolled

Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

Completed·JJohn Sampson·Phase 1·NCT00626015·16 enrolled

Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme

Completed·—·Phase 2·NCT00003464·50 enrolled

Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

Terminated·—·Phase 1·NCT00915694·15 enrolled

Glioma22 trials

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Active, not recruiting·EEastern Cooperative Oncology Group·Phase 3·NCT00978458·540 enrolled

A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT01891747·14 enrolled

Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy

Completed·MMayo Clinic·Phase 4·NCT06625047·30 enrolled

Show 19 more trials

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

Terminated·TTocagen Inc.·Phase 2/3·NCT02414165·403 enrolled

Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma

Terminated·UUniversity of Nebraska·Phase 1·NCT02168270·4 enrolled

Temozolomide in Treating Patients With Progressive Low-Grade Glioma

Completed·—·Phase 2·NCT00003466·100 enrolled

Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

Terminated·MMustafa Khasraw, MBChB, MD, FRCP, FRACP·Phase 2·NCT03927222·6 enrolled

18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy

Completed·MMayo Clinic·Phase 2·NCT01991977·91 enrolled

Treatment Strategy for Low-grade Gliomas

Terminated·SSun Yat-sen University·Phase 3·NCT00897377·500 enrolled

Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas

Withdrawn·WWashington University School of Medicine·Phase 1·NCT02976441

Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

Terminated·NNorthwestern University·Phase 2·NCT01478321·54 enrolled

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Completed·JJulie Krystal·Phase 1/2·NCT01837862·36 enrolled

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Recruiting·UUniversity of California, San Francisco·Phase 1/2·NCT06504381·70 enrolled

Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

Terminated·SSantosh Kesari·Phase 1·NCT02507232·2 enrolled

6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00504660·75 enrolled

Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas

Completed·CChildren's Oncology Group·Phase 2·NCT00100802·118 enrolled

Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins··NCT00471653·10 enrolled

Temozolomide and Radiation Therapy in Treating Patients With Gliomas

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00114140·136 enrolled

Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma

Completed·CChildren's Oncology Group·N/A·NCT00077207·66 enrolled

Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma

Withdrawn·NNYU Langone Health·Phase 2·NCT00006263

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT01236560·101 enrolled

Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Unknown status·HHebei Yanda Hospital·N/A·NCT02416999·30 enrolled

Malignant Glioma8 trials

Temozolomide in Treating Patients With Recurrent Malignant Glioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00004113

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy

Completed·MMayo Clinic·Phase 2·NCT03778294·43 enrolled

Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma

Completed·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT00052455·500 enrolled

Show 5 more trials

Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors

Completed·—·Phase 1/2·NCT00005952·30 enrolled

Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma

Unknown status·KKentuckiana Cancer Institute·Phase 2·NCT00283543·40 enrolled

Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas

Not yet recruiting·TThe First People's Hospital of Changzhou·Phase 4·NCT02496988·120 enrolled

Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas

Not yet recruiting·TThe First People's Hospital of Changzhou·Phase 1/2·NCT02494804·80 enrolled

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

Completed· AbbVie logo

AbbVie·Phase 1/2·NCT02590263·53 enrolled

Temozolomide7 trials

Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)

Completed· Merck & Co. logo

Merck & Co.··NCT00723827·682 enrolled

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Recruiting·NNationwide Children's Hospital·Phase 1/2·NCT04211675·31 enrolled

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Completed· AbbVie logo

AbbVie·Phase 1·NCT00526617·41 enrolled

Show 4 more trials

Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00003304·29 enrolled

Study of MLN8237 in Combination With Irinotecan and Temozolomide

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1/2·NCT01601535·54 enrolled

Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00006358·44 enrolled

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients

Completed·IIstituto Oncologico Veneto IRCCS·Phase 1·NCT06095375·21 enrolled

56 more indications

Lymphoma6 trials

Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma

Withdrawn·TThe Methodist Hospital Research Institute·N/A·NCT00109798

Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

Unknown status·HHuiqiang Huang·Phase 2·NCT04514393·33 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00098774·47 enrolled

Show 3 more trials

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated·—·Phase 1·NCT00003567·8 enrolled

Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma

Unknown status·RRongjie Tao·Phase 2·NCT01735747·16 enrolled

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT03495960·72 enrolled

Refractory Solid Tumors5 trials

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Suspended·NNational Cancer Institute (NCI)·Phase 1/2·NCT04890093·64 enrolled

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

Completed·CChildren's Oncology Group·Phase 1·NCT00138216·42 enrolled

Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01141244·72 enrolled

Show 2 more trials

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT03709680·128 enrolled

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06006273·48 enrolled

Metastatic Melanoma4 trials

Ipilimumab + Temozolomide in Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01119508·64 enrolled

Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma

Unknown status·SSt. Luke's Medical Center·Phase 1·NCT00016055·18 enrolled

Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma

Completed·NNorthwestern University·Phase 1/2·NCT00301067·20 enrolled

Show 1 more trial

Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

Unknown status·IInstitut Curie·Phase 2·NCT01217398·35 enrolled

Melanoma4 trials

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00068666·41 enrolled

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Completed·—·Phase 2·NCT00602576·169 enrolled

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Recruiting·KKari Kendra·Phase 1/2·NCT05588453·30 enrolled

Show 1 more trial

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00521001·49 enrolled

Newly Diagnosed3 trials

Study of Pamiparib in Newly Diagnosed and rGBM

Active, not recruiting·NNader Sanai·Phase 1·NCT04614909·45 enrolled

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors

Completed·PPatrick Y. Wen, MD·Phase 1/2·NCT00441142·119 enrolled

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Active, not recruiting·TTheodore S. Johnson·Phase 2·NCT04049669·130 enrolled

Non-Small Cell Lung Cancer3 trials

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00005037·51 enrolled

Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00632203·53 enrolled

Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00080938·26 enrolled

Neuroblastoma3 trials

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

Completed·—·Phase 2·NCT00098865·15 enrolled

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06995872·34 enrolled

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Terminated· Novartis logo

Novartis·Phase 1·NCT05429502·12 enrolled

Ewing's Sarcoma3 trials

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Terminated·GGradalis, Inc.·Phase 3·NCT03495921·32 enrolled

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Terminated·SStanford University·Phase 2·NCT01313884·3 enrolled

Aerosol L9-NC and Temozolomide in Ewing's Sarcoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00492141·10 enrolled

Lung Cancer3 trials

Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00266812·35 enrolled

Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00034697·24 enrolled

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Active, not recruiting·DDwight Owen·Phase 2·NCT03728361·55 enrolled

Radiation Therapy3 trials

Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00262730·97 enrolled

Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00302159·43 enrolled

Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00004068·53 enrolled

Brain Metastases3 trials

Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00026494·49 enrolled

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

Completed·OOhio State University Comprehensive Cancer Center·Phase 1/2·NCT00362817·17 enrolled

Temozolomide in Treating Patients With Brain Metastases

Completed·—·Phase 2·NCT00005954

Small Cell Lung Cancer3 trials

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT03554473·37 enrolled

Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00740636·92 enrolled

Temozolomide as Maintenance Therapy in Small Cell Lung Cancer

Unknown status·—·Phase 2·NCT01900951·60 enrolled

Recurrent or Refractory Solid Tumors2 trials

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00077454·95 enrolled

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Completed·CChildren's Oncology Group·Phase 1·NCT02975882·33 enrolled

Soft Tissue Sarcoma2 trials

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00003718·25 enrolled

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Active, not recruiting·—·Phase 2·NCT04200443·72 enrolled

Medulloblastoma2 trials

Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway

Terminated·CCentre Leon Berard·Phase 1/2·NCT01601184·24 enrolled

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Recruiting·NNationwide Children's Hospital·Phase 2·NCT05096481·120 enrolled

Anaplastic Astrocytoma2 trials

Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT03224104·71 enrolled

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03528642·40 enrolled

GBM2 trials

DC Migration Study for Newly-Diagnosed GBM

Completed·MMustafa Khasraw, MBChB, MD, FRCP, FRACP·Phase 2·NCT02366728·64 enrolled

UNITE Study: Understanding New Interventions With GBM ThErapy

Terminated· AbbVie logo

AbbVie·Phase 3·NCT03419403·40 enrolled

Neuroendocrine Carcinoma2 trials

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06202066·60 enrolled

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Terminated·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT03387592·53 enrolled

Ewing sarcoma2 trials

Irinotecan and Temozolomide for Ewing Sarcoma

Unknown status·PPeking University People's Hospital·Phase 2·NCT03359005·60 enrolled

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT04901702·90 enrolled

Diffuse Intrinsic Pontine Glioma2 trials

A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas

Completed·—·Phase 1·NCT00890786·27 enrolled

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Terminated·—·Phase 2·NCT01182350·53 enrolled

Central Nervous System Lymphoma2 trials

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

Recruiting·HHenan Cancer Hospital·Phase 2·NCT04737889·30 enrolled

Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma

Unknown status·GGuangdong Provincial People's Hospital·Phase 2·NCT02934204·51 enrolled

Effectiveness2 trials

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT05691491·58 enrolled

The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM

Not yet recruiting·SSouthern Medical University, China·Phase 2·NCT06218524·200 enrolled

First-line Treatment1 trial

Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic

Unknown status·YYunpeng Liu·Phase 2·NCT02972320·60 enrolled

Advanced Solid Tumors1 trial

A Safety Study in Participants With Advanced Solid Tumors

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT01284335·234 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT05247905·31 enrolled

Locally-advanced Rectal Cancer1 trial

Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer

Recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT05136326·21 enrolled

Neuroendocrine Tumors1 trial

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Completed·—·Phase 2·NCT00137774·34 enrolled

Metastatic Solid Tumors1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

Leiomyosarcoma1 trial

Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00033709

Clinical Trial1 trial

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT05999994·105 enrolled

Pediatric Solid Tumors1 trial

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Withdrawn·WWashington University School of Medicine·Phase 2·NCT02689336

Neuroendocrine Tumor1 trial

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 1·NCT02831179

Acute Leukemia1 trial

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01139970·66 enrolled

Primitive Neuroectodermal Tumor1 trial

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01217437·108 enrolled

Colorectal Cancer1 trial

A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

Completed·GGeorgetown University·Phase 2·NCT01051596·75 enrolled

Breast Cancer1 trial

Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00638963·6 enrolled

Brain Cancer1 trial

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Recruiting·TTheodore S. Johnson·Phase 1·NCT05106296·37 enrolled

Central Nervous System1 trial

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

Terminated·TTufts Medical Center·Phase 1·NCT00629187·2 enrolled

Malignant Brain Tumors1 trial

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Completed·NNewLink Genetics Corporation·Phase 1/2·NCT02052648·160 enrolled

Brain Tumors1 trial

FMISO-PET in Brain Tumors and SCS Effect

Terminated·—·Phase 2·NCT01868906·6 enrolled

Anaplastic Oligodendroglioma1 trial

Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00033280·42 enrolled

Capecitabine1 trial

Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study

Completed·AAustralasian Gastro-Intestinal Trials Group·Phase 2·NCT02358356·75 enrolled

Rectal Cancer1 trial

Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer

Completed·—·Phase 1·NCT01781403·22 enrolled

Peritoneal Cancer1 trial

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT02836028

Patients With Advanced Solid Tumors1 trial

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT00811993·104 enrolled

Concentration1 trial

Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02389738·6 enrolled

Gastrointestinal Stromal Tumor1 trial

Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

Active, not recruiting·—·Phase 2·NCT03556384·23 enrolled

Whole-Brain Radiotherapy1 trial

Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment

Completed·IInstituto Nacional de Cancerologia de Mexico·Phase 2·NCT01015534·55 enrolled

Tumor1 trial

Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM

Terminated·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 1/2·NCT02085304·8 enrolled

Adenoma1 trial

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03930771·1 enrolled

Bladder Cancer1 trial

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Terminated·XXennials Therapeutics Australia Pty Ltd·Phase 1/2·NCT04851834·12 enrolled

Neuroendocrine Cancer1 trial

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04394858·46 enrolled

Liver Cancer1 trial

ABT-888 and Temozolomide for Liver Cancer

Terminated·GGeorgetown University·Phase 2·NCT01205828·16 enrolled

Solid Tumors1 trial

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Completed·AAbbott·Phase 2·NCT01193140·24 enrolled

Low Grade Glioma1 trial

Trial in Low Grade Glioma Patients: Wait or Treat

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT03763422·19 enrolled

Surgical1 trial

Surgical Pembro +/- Olaparib w TMZ for rGBM

Recruiting·—·Phase 2·NCT05463848·78 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 11, 1999

TEMODAR

NDA NDA021029

Feb 27, 2009

TEMODAR

NDA NDA022277

Sources

References

[1]
ClinicalTrials.gov — 748 trial records for temozolomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Temodar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — temozolomide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for temozolomide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022277). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Temodar

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Glioblastoma38 trials

Glioblastoma Multiforme28 trials

Glioma22 trials

Malignant Glioma8 trials

Temozolomide7 trials

Lymphoma6 trials

Refractory Solid Tumors5 trials

Metastatic Melanoma4 trials

Melanoma4 trials

Newly Diagnosed3 trials

Non-Small Cell Lung Cancer3 trials

Neuroblastoma3 trials

Ewing's Sarcoma3 trials

Lung Cancer3 trials

Radiation Therapy3 trials

Brain Metastases3 trials

Small Cell Lung Cancer3 trials

Recurrent or Refractory Solid Tumors2 trials

Soft Tissue Sarcoma2 trials

Medulloblastoma2 trials

Anaplastic Astrocytoma2 trials

GBM2 trials

Neuroendocrine Carcinoma2 trials

Ewing sarcoma2 trials

Diffuse Intrinsic Pontine Glioma2 trials

Central Nervous System Lymphoma2 trials

Effectiveness2 trials

First-line Treatment1 trial

Advanced Solid Tumors1 trial

Pancreatic Neuroendocrine Tumor1 trial

Locally-advanced Rectal Cancer1 trial

Neuroendocrine Tumors1 trial

Metastatic Solid Tumors1 trial

Leiomyosarcoma1 trial

Clinical Trial1 trial

Pediatric Solid Tumors1 trial

Neuroendocrine Tumor1 trial

Acute Leukemia1 trial

Primitive Neuroectodermal Tumor1 trial

Colorectal Cancer1 trial

Breast Cancer1 trial

Brain Cancer1 trial

Central Nervous System1 trial

Malignant Brain Tumors1 trial

Brain Tumors1 trial

Anaplastic Oligodendroglioma1 trial

Capecitabine1 trial

Rectal Cancer1 trial

Peritoneal Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Concentration1 trial

Gastrointestinal Stromal Tumor1 trial

Whole-Brain Radiotherapy1 trial

Tumor1 trial

Adenoma1 trial

Bladder Cancer1 trial

Neuroendocrine Cancer1 trial

Liver Cancer1 trial

Solid Tumors1 trial

Low Grade Glioma1 trial

Surgical1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News